{
  "docId": "019dd923-5fec-763b-95d0-6c2b37f81466",
  "docSlug": "bi-9523b367be63361f",
  "documentTitle": "3T Biosciences 27-slide pitch deck to raise $40M Series A",
  "authorId": "Pitchdecks",
  "authorName": "3T Biosciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.6,
  "pageNumber": 18,
  "pageCount": 27,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a comparative case study format to validate the platform's efficacy in protein engineering.",
  "elementsJson": [
    "headline_text",
    "action_title",
    "screenshot",
    "heatmap",
    "line_chart",
    "callout_box"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5fec-763b-95d0-6c2b37f81466/18",
  "deckHref": "/decks/019dd923-5fec-763b-95d0-6c2b37f81466",
  "deckJsonHref": "/decks/019dd923-5fec-763b-95d0-6c2b37f81466.json",
  "deckAnchorHref": "/decks/019dd923-5fec-763b-95d0-6c2b37f81466#slide-18",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Titin – known fatal OTOT; FAT2–newly identified target",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-c0aa-76ce-98bf-d83898229b63",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.3,
        "x": 0.35,
        "y": 0.34
      },
      "kind": "chart",
      "text": "A3A vs 94a-14 peptide position amino acid heatmap",
      "attrs": null,
      "subkind": "heatmap",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9d832920-901a-4e8c-b3fe-81e98c1da905",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.3,
        "x": 0.68,
        "y": 0.34
      },
      "kind": "chart",
      "text": "A3A TCR and 94a-14 TCR CD69 MFI vs log10[peptide] (M) plots",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "66a17338-ca10-4f14-9dcf-846a5675deec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.3,
        "x": 0.02,
        "y": 0.34
      },
      "kind": "image",
      "text": "Zhao et al., Science 2022 research summary",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bee7904d-f349-41c3-9946-950772e28577",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "CD69 MFI",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-c0aa-76ce-98bf-e2f7213f8537",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.25,
        "x": 0.7,
        "y": 0.88
      },
      "kind": "paragraph",
      "text": "Titin – known fatal OTOT\nFAT2-newly identified target",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3f35cc49-2d7d-48de-93f1-5ca354972839",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.35,
        "y": 0.88
      },
      "kind": "paragraph",
      "text": "A3a- clinically toxic TCR\n94a-14 catch bond engineered TCR",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3f615a18-9e84-4561-bb00-bd5d80c7f96d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "Zhao et al., Science 2022",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd952-c0aa-76ce-98bf-dcbde0965422",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.04,
        "y": 0.13
      },
      "kind": "title",
      "text": "Case Study: Clinically toxic A3a TCR recognizing the on-target MAGE-A3 peptide and off-target Titin engineered to eliminate cross-reactivity",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "50d5eefe-59ef-4e52-b762-9a8837fd2434",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "Use of Functional Selections Enabled by 3T-TRACE To Derive BIC-TCRs",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c2f9e173-5dc4-463c-b803-465a9961ebd3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "before-after-bridge",
      "slug": null,
      "matchId": "67abae01-d6bd-41ab-8453-e35ab6f14d9c",
      "evidence": "Shows the transition from a toxic TCR (A3a) to an engineered safe TCR (94a-14) using the 3T-TRACE platform.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 19,
      "from": 17,
      "beatId": "73a34dcb-2314-48dd-b4f8-88d5ee73c244",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "Slides 17-19 agitate the problem by highlighting the limitations of current immunotherapies and the need for better solutions",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 19,
      "from": 17,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "b4672338-76bf-4840-8e57-d1ec2e6417b2",
      "evidence": "The deck highlights the significant unmet need in solid tumor cancers and the limitations of current immunotherapies",
      "position": 0,
      "objective": "Highlight the cost of inaction in solid tumor cancer treatment",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}